These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20205269)

  • 21. A transition model for quality-of-life data with non-ignorable non-monotone missing data.
    Liao K; Freres DR; Troxel AB
    Stat Med; 2012 Dec; 31(28):3444-66. PubMed ID: 22826030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mixed model for repeated dilution assays.
    Bloch J; Chavance M
    Biometrics; 1998 Jun; 54(2):482-92. PubMed ID: 9629640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Delta trial.
    Zaretsky MD
    Lancet; 1997 Feb; 349(9048):358-9. PubMed ID: 9024402
    [No Abstract]   [Full Text] [Related]  

  • 24. Bayesian modeling of the covariance structure for irregular longitudinal data using the partial autocorrelation function.
    Su L; Daniels MJ
    Stat Med; 2015 May; 34(12):2004-18. PubMed ID: 25762065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple imputation for non-monotone missing not at random data using the no self-censoring model.
    Ren B; Lipsitz SR; Weiss RD; Fitzmaurice GM
    Stat Methods Med Res; 2023 Oct; 32(10):1973-1993. PubMed ID: 37647237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Models for empirical Bayes estimators of longitudinal CD4 counts.
    LaValley MP; DeGruttola V
    Stat Med; 1996 Nov 15-30; 15(21-22):2289-305; discussion 2337-40. PubMed ID: 8931202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation and comparison of rates of change in longitudinal studies with informative drop-outs.
    Touloumi G; Pocock SJ; Babiker AG; Darbyshire JH
    Stat Med; 1999 May; 18(10):1215-33. PubMed ID: 10363341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semiparametric approach for non-monotone missing covariates in a parametric regression model.
    Sinha S; Saha KK; Wang S
    Biometrics; 2014 Jun; 70(2):299-311. PubMed ID: 24571224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness.
    Cole BF; Bonetti M; Zaslavsky AM; Gelber RD
    Stat Med; 2005 Aug; 24(15):2317-34. PubMed ID: 15977292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interpretable inference on the mixed effect model with the Box-Cox transformation.
    Maruo K; Yamaguchi Y; Noma H; Gosho M
    Stat Med; 2017 Jul; 36(15):2420-2434. PubMed ID: 28294388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating cumulative probabilities from incomplete longitudinal binary responses with application to HIV vaccine trials.
    Hudgens MG
    Stat Med; 2003 Feb; 22(3):463-79. PubMed ID: 12529875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Marginalized transition models for longitudinal binary data with ignorable and non-ignorable drop-out.
    Kurland BF; Heagerty PJ
    Stat Med; 2004 Sep; 23(17):2673-95. PubMed ID: 15316952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doubly robust estimation in missing data and causal inference models.
    Bang H; Robins JM
    Biometrics; 2005 Dec; 61(4):962-73. PubMed ID: 16401269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimation in regression models for longitudinal binary data with outcome-dependent follow-up.
    Fitzmaurice GM; Lipsitz SR; Ibrahim JG; Gelber R; Lipshultz S
    Biostatistics; 2006 Jul; 7(3):469-85. PubMed ID: 16428260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weighted estimating equations for longitudinal studies with death and non-monotone missing time-dependent covariates and outcomes.
    Shardell M; Miller RR
    Stat Med; 2008 Mar; 27(7):1008-25. PubMed ID: 17579923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of longitudinal Gaussian data with missing data on the response variable].
    Jacqmin-Gadda H; Commenges D; Dartigues J
    Rev Epidemiol Sante Publique; 1999 Dec; 47(6):525-34. PubMed ID: 10673586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demystifying optimal dynamic treatment regimes.
    Moodie EE; Richardson TS; Stephens DA
    Biometrics; 2007 Jun; 63(2):447-55. PubMed ID: 17688497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Infection with Mycobacterium genavense in 2 HIV-seropositive patients in Amsterdam].
    van Ginneken EE; Koopmans PP
    Ned Tijdschr Geneeskd; 1998 Jul; 142(28):1629. PubMed ID: 9763851
    [No Abstract]   [Full Text] [Related]  

  • 40. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
    Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
    Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.